

Disclosures

Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Biomarin	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
BMS	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cardior	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
Cytokinetics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
DinaQor	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
Pfizer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Sanofi/Genzyme	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Sarepta	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (3)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Peer View	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
PeerVoice	Speaker's Bureau	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Radcliffe Medical	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Cardiomyopathy UK	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Heart Failure and Cardiomyopathies
European Society of Cardiology	Other - <i>Chairman ESC Academy & ESC Board Member</i>	None (\$0)	Heart Failure and Cardiomyopathies
European Society of Cardiology	Other - <i>Chairman ESC Guideline on Hypertrophic Cardiomyopathy 2012-14</i>	None (\$0)	Heart Failure and Cardiomyopathies
International Cardiomyopathy Network	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Heart Failure and Cardiomyopathies

Clinical Trial Enroller (2)

Trial Name	Trial Sponsor	Trial Funding Source
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation	Array Pharma	
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy	MyoKardia	

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
multiple	Significant (>= \$5,000)

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 3/7/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 3/7/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 3/7/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.